142 related articles for article (PubMed ID: 32315662)
1. Dissolution and Permeability Properties of Co-Amorphous Formulations of Hydrochlorothiazide.
Ruponen M; Rusanen H; Laitinen R
J Pharm Sci; 2020 Jul; 109(7):2252-2261. PubMed ID: 32315662
[TBL] [Abstract][Full Text] [Related]
2. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
3. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer.
Sormunen H; Ruponen M; Laitinen R
Int J Pharm; 2019 Oct; 570():118653. PubMed ID: 31472218
[TBL] [Abstract][Full Text] [Related]
4. Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.
Ruponen M; Kettunen K; Santiago Pires M; Laitinen R
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33514009
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
6. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.
Moinuddin SM; Ruan S; Huang Y; Gao Q; Shi Q; Cai B; Cai T
Int J Pharm; 2017 Oct; 532(1):393-400. PubMed ID: 28893583
[TBL] [Abstract][Full Text] [Related]
7. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
8. Improved in vitro and in vivo properties of telmisartan in the co-amorphous system with hydrochlorothiazide: A potential drug-drug interaction mechanism prediction.
Shi X; Zhou X; Shen S; Chen Q; Song S; Gu C; Wang C
Eur J Pharm Sci; 2021 Jun; 161():105773. PubMed ID: 33640500
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
10. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.
Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T
Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842
[TBL] [Abstract][Full Text] [Related]
11. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
12. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
13. A Mechanistic Study of Drug Mass Transport from Supersaturated Solutions Across PAMPA Membranes.
Hate SS; Mosquera-Giraldo LI; Taylor LS
J Pharm Sci; 2022 Jan; 111(1):102-115. PubMed ID: 34237298
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo relationship for amorphous solid dispersions using a double membrane dissolution-permeation setup.
Jørgensen JR; Mohr W; Rischer M; Sauer A; Mistry S; Rades T; Müllertz A
Eur J Pharm Biopharm; 2023 Jul; 188():26-32. PubMed ID: 37146739
[TBL] [Abstract][Full Text] [Related]
15. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions.
Löbmann K; Strachan C; Grohganz H; Rades T; Korhonen O; Laitinen R
Eur J Pharm Biopharm; 2012 May; 81(1):159-69. PubMed ID: 22353489
[TBL] [Abstract][Full Text] [Related]
16. Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase.
Huang R; Han J; Wang R; Zhao X; Qiao H; Chen L; Li W; Di L; Zhang W; Li J
Eur J Pharm Sci; 2019 Mar; 130():147-155. PubMed ID: 30699368
[TBL] [Abstract][Full Text] [Related]
17. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
18. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
19. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
20. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review.
Kapoor DU; Singh S; Sharma P; Prajapati BG
AAPS PharmSciTech; 2023 Dec; 24(8):253. PubMed ID: 38062314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
